Boston Scientific Corp. v. Cordis Corp.

422 F. Supp. 2d 1102, 2006 U.S. Dist. LEXIS 11208, 2006 WL 496052
CourtDistrict Court, N.D. California
DecidedMarch 1, 2006
DocketC 02-01474 JW
StatusPublished

This text of 422 F. Supp. 2d 1102 (Boston Scientific Corp. v. Cordis Corp.) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Boston Scientific Corp. v. Cordis Corp., 422 F. Supp. 2d 1102, 2006 U.S. Dist. LEXIS 11208, 2006 WL 496052 (N.D. Cal. 2006).

Opinion

ORDER (1) GRANTING IN PART PLAINTIFFS’ MOTION FOR SUMMARY JUDGMENT STRIKING IN PART AFFIRMATIVE DEFENSE OF INVALIDITY BY ANTICIPATION; (2) GRANTING IN PART PLAINTIFFS’ MOTION FOR SUMMARY JUDGMENT STRIKING IN PART AFFIRMATIVE DEFENSE OF PRIORITY OF INVENTOR-SHIP

WARE, District Judge.

I. INTRODUCTION

Boston Scientific Corporation and Target Corporation (“Plaintiffs”) filed this action against Cordis Corporation (“Defendant” or “Cordis”) alleging infringement of a number of patents that they hold on methods and devices used for treating aneurysms.

On June 25, 2004, the Court granted Plaintiffs’ motion for summary judgment of literal infringement of the U.S. patent numbered 6,238,415 (“the '415 patent”). (See Docket Item No. 582.) On November 14, 2005, the Court denied Defendants’ motion for summary judgment of invalidity of the '415 patent and granted in part Plaintiffs’ motion for summary judgment striking in part affirmative defense of invalidity by anticipation. (See Docket Item No. 847.)

Before the Court are Plaintiffs’ motions for summary judgment. In one motion, Plaintiffs seek to have the Court declare the validity of claim 27 of the '415 patent on the ground that it is not anticipated by a series of other patents which were not raised previously by Cordis. In the other motion, Plaintiffs seek to have the Court declare that the activities previously completed by Lawrence Livermore National Laboratories (“LLNL”) in conjunction with Cordis do not invalidate the '415 patent. Through these motions, Plaintiffs are essentially seeking to have the Court strike Cordis’ affirmative defenses of anticipation and priority of inventorship.

A hearing was held on November 14, 2005. Based on all the papers filed to date and the oral arguments, the Court GRANTS in part and DENIES in part Plaintiffs’ motions for summary judgment.

II. BACKGROUND

The '415 patent discloses its invention as a mechanical occlusive implant delivery assembly having a rapid response decoupling or detachment mechanism that does not effect significant migration of the implant during release. '415 patent, col. 2, 1. 66— col. 3, 1. 14. A complete background of the technology is contained in the Court’s October 7, 2003 Claims Construction Order (hereafter Markman Order).

*1105 A. Infringed Claims of the '415 Patent

The Court granted summary judgment in favor of Plaintiffs that Defendant infringed claims 16, 17, 19, 28, 24, 25, 27, 29, 34, and 35 of the '415 patent (“infringed claims”) through Defendant’s manufacture and sale of TRUFILL DCS Detachable Coil Systems intended to embolize aneurysms. 1 Defendant focuses its challenge to the validity of the '415 patent on the infringed claims. The claims at issue are listed below:

16. An implant delivery assembly for occluding a site in a mammal, the assembly comprising:
an occlusive implant, a pusher having a proximal section and a distal section, a selectively operable coupling for attaching the implant to the pusher distal section, said coupling operable by fluid pressure so that when a sufficient amount of fluid pressure is applied to the coupling, the fluid pressure causes the occlusive implant to separate from the pusher.
17. The implant delivery assembly of claim 16 wherein the coupling is a locking member that holds the occlusive implant during delivery and releases the occlusive implant upon the application of the fluid pressure such that the occlusive implant detaches from the pusher at the desired delivery site.
19. The implant delivery assembly of claim 17 wherein the occlusive implant is a coil having a proximal end and a distal end, wherein the proximal end of the coil is adapted to engage the coupling.
23. The implant delivery assembly of claim 16 wherein the fluid comprises a liquid.
24. The implant delivery assembly of claim 16 wherein the pusher comprises a tube.
25.The implant delivery assembly of claim 24 wherein the tube is a metal tube.
27. The implant delivery assembly of claim 16 wherein the coupling comprises a tube.
29. The implant delivery assembly of claim 27 wherein the coupling is a plastic tube.
34. A method for rapidly detaching an occlusive implant into a mammalian site comprising the steps of:
a) introducing an assembly comprising
I. the occlusive implant,
ii. a pusher having a distal section and a proximal section, and
iii. a coupling, wherein the occlusive implant is attached to the pusher distal section at the coupling, into the mammalian site, and
b) delivering the occlusive implant to the mammalian site by applying sufficient fluid pressure to the assembly so that the occlusive implant disengages from the pusher distal section at the coupling.
35. A method for rapidly detaching an occlusive implant into a body cavity comprising the steps of:
a) introducing into a body cavity an assembly comprising an occlusive implant that is detachable affixed to a pusher, and
b) delivering fluid pressure through the pusher such that the implant detaches from the pusher by the fluid pressure.

*1106 B. Claims Construction in the '415 Patent

On September 19, 2003, the Court held a hearing in accordance with Markman v. Westview Instruments, Inc., 517 U.S. 370, 116 S.Ct. 1384, 134 L.Ed.2d 577 (1996), to construe the disputed terms and phrases of the asserted claims. The Court’s October 7, 2003 Order Following Claims Construction Hearing construed the following disputed terms in the '415 patent which are relevant to the present findings on validity and invalidity:

Disputed Claim Language “implant delivery assembly”

“pusher”

“selectively operable coupling”

“coupling”

“said coupling operable by fluid pressure so that when a sufficient amount of fluid pressure is applied to the coupling, the fluid pressure causes the occlusive implant to separate from the pusher”

“delivering fluid pressure through the pusher such that the implant detaches from the pusher by the fluid pressure”_

Court’s Construction

“an apparatus for delivery of occlusive devices, such as embolic coils that comprises three distinct components: a pusher, a coupling, and an implant”_

“any device or structure intended to push another device or structure”_

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Masson v. New Yorker Magazine, Inc.
501 U.S. 496 (Supreme Court, 1991)
Smithkline Beecham Corp. v. Apotex Corp.
403 F.3d 1331 (Federal Circuit, 2005)
Hahn v. Wong
892 F.2d 1028 (Federal Circuit, 1989)
F. Brantley Scott and John H. Burton v. Roy P. Finney
34 F.3d 1058 (Federal Circuit, 1994)
Telemac Cellular Corporation v. Topp Telecom, Inc.
247 F.3d 1316 (Federal Circuit, 2001)
John M. Taskett v. Dale H. Dentlinger
344 F.3d 1337 (Federal Circuit, 2003)
Chrimar Systems, Inc. v. Cisco Systems, Inc.
318 F. Supp. 2d 476 (E.D. Michigan, 2004)
Advanced Display Systems, Inc. v. Kent State University
212 F.3d 1272 (Federal Circuit, 2000)
Eli Lilly & Co. v. Barr Laboratories, Inc.
251 F.3d 955 (Federal Circuit, 2001)
Schering Corp. v. Geneva Pharmaceuticals, Inc.
339 F.3d 1373 (Federal Circuit, 2003)

Cite This Page — Counsel Stack

Bluebook (online)
422 F. Supp. 2d 1102, 2006 U.S. Dist. LEXIS 11208, 2006 WL 496052, Counsel Stack Legal Research, https://law.counselstack.com/opinion/boston-scientific-corp-v-cordis-corp-cand-2006.